Bio-Thera Solutions

About Bio-Thera Solutions

Bio-Thera Solutions is a Guangzhou-based, commercial-stage biopharmaceutical company that develops biosimilars and novel antibody-based therapies for cancer, autoimmune, cardiovascular, and other serious diseases. Listed on Shanghai's STAR Market, the company combines in-house biologics research, development, and manufacturing with a network of regional partners — including STADA, Hikma, Gedeon Richter, Intas, and Dr. Reddy's — who handle regulatory filing and commercialization outside China. Bio-Thera's approved biosimilars include products referencing adalimumab, ustekinumab, tocilizumab, bevacizumab, and golimumab, sold under regional brand names such as QLETLI, STARJEMZA, and TOFIDENCE. Beyond biosimilars, the company is advancing an oncology pipeline of proprietary antibodies and antibody-drug conjugates aimed at post-PD-1 immuno-oncology, positioning itself as a bridge between affordable biosimilar medicine and next-generation biologic innovation.

Biopharmaceuticals, biosimilars, antibody therapeutics, oncology, monoclonal antibodies, drug development, autoimmune disease, China biotech